Cytokinetics Secures First FDA Approval for Heart Drug

Cytokinetics secured its first U.S. drug approval on Friday, October 27, 2023. The Food and Drug Administration cleared Myqorzo for the treatment of obstructive hypertrophic cardiomyopathy, which is an inherited heart disorder.

Cytokinetics plans to begin selling Myqorzo in late January, although the price has not yet been disclosed. This approval marks a significant milestone for Cytokinetics, which has been working for 27 years to achieve this outcome.

Myqorzo will compete with a similar drug from Bristol Myers Squibb, which was approved in 2022 and is currently generating over $1 billion in annual sales.